ClinicalTrials.gg
CompletedNCT06287255EIM+Updated Nov 5, 2026

Feasibility and Acceptability of Incorporating Smartwatches Into an Exercise is Medicine Program in Older Individuals

An interventional study of EIM+ in Physical Inactivity and Obesity, sponsored by Ohio State University. Completed at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ohio State University · Not applicable, Interventional, and Prevention

How we know

Updated Nov 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 452 studies in Sedentary Behavior with a site in United States — 61 open to participants now, 89 under way, none of them phase 3. Sedentary Behavior · United States.

Enrollment
147th of 421
85 · median 60
Started
2024
with 38 others
No phase
386 of 452
54 open now
Registered
380th of 452
by date

Among the 452 studies in Sedentary Behavior with a site in United States, this one is the 147th largest by enrollment of the 421 interventional ones that give a count, is one of 39 that started in 2024, is one of 386 with no phase, and was the 380th registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

61 of the 452 studies in Sedentary Behavior with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 452 studies in Sedentary Behavior with a site in United States, or all of them as a file.
02

Study summary

The effects of exercise on prevention and improved control of chronic diseases, reduced mortality, and improved quality of life are well established. Exercise has been shown to prevent heart disease, stroke, type 2 diabetes, depression, and certain types of cancers. In addition to prevention, physical activity is included in the standard or care for many chronic diseases and used in treatment. For example, the American Diabetes Association has identified positive health behaviors like physical activity as foundational in the treatment and management of disease and improving overall quality of life.

The Ohio State University Wexner Medical Center Exercise is Medicine Program (EIM) is a physician referral program that aims to increase physical activity to prevent and reduce complications from chronic disease.

The integration of technology among a 65+ population of EIM participants provides a novel approach to improving individual's health. Thus, our study aims to provide EIM participants aged 65+ with smartwatches in the hopes of increasing their overall physical activity levels.

03

Conditions studied

  • Physical Inactivity
  • Obesity
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65+
  • No healthcare provider-imposed limitations on physical activity
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Symptoms suggestive of coronary artery disease (CAD) or congestive heart failure (CHF) (i.e. chest pain, dizziness, syncope, excessive dyspnea on exertion)
  • Myocardial infarction within the last 12 months
  • Revascularization within the last 12 months
  • Stroke/ (TIA) within the past 12 months
  • Unstable angina
  • Congestive heart failure ( (NYHA) Class II, III or IV)
  • Ventricular arrhythmia
  • cardiac valve disease
  • Blood pressure >160/100 mmHg
  • Uncontrolled seizure disorder
  • Major surgery within the past three months
  • Severe or frequent hypoglycemia
  • Inability to independently manage blood glucose during activity
  • Severe autonomic or peripheral neuropathy
  • Active foot ulcers
  • Unstable retinopathy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Exercise is Medicine Plus

    Participants receiving the Exercise is Medicine program along with a smartwatch.

    Behavioral: EIM+

Interventions

  • BehavioralEIM+

    The Exercise is Medicine (EIM) program involves a personalized exercise prescription and wellness coaching component. At the first 1:1 session, participants are provided with a Fitbit and onboarded with Fitabase, allowing for documentation of baseline health behaviors. Over the course of the program, the EIM fitness specialist reviews Fitbit data and progress towards goals, sending push notifications for encouragement and reminders. A personal training session is conducted, followed by sixteen group sessions including up to eight participants. The final session includes updating goals, incorporating Fitbits, and providing an updated exercise prescription. Upon program completion, participants will attend monthly webinars and health coaching sessions at 6- and 12-months post-program. The program aims to help individuals overcome barriers and maintain long-term exercise self-efficacy.

06

What researchers measure

Primary outcomes

  1. Feasibility of EIM+

    The co-primary outcome is to determine the feasibility of utilizing smartwatches among Exercise is Medicine participants aged 65+ as assessed by the number of eligible referrals agreeing to participate in the intervention, program attendance, and completion rates.

    Time frame: 12 months

  2. Acceptability of EIM+

    The co-primary outcome is to determine the acceptability of utilizing smartwatches among Exercise is Medicine (EIM) participants aged 65+ as assessed by survey responses on perception of wearable devices integrated in to the EIM program and program attendance and completion rates.

    Time frame: 12 months

Secondary outcomes

  1. Change in physical activity

    The secondary outcome of physical activity levels before, during and after program completion (preliminary efficacy) will be examined both continuously (moderate-vigorous physical activity minutes per week) and categorically (meeting the goal of 150 minutes of moderate-vigorous physical activity per week).

    Time frame: 12 months

  2. Change in weight

    The secondary outcome is weight before, during and after program completion

    Time frame: 12 months

  3. Change in BMI

    The secondary outcome is BMI before, during and after program completion

    Time frame: 12 months

  4. Change in hip circumference

    The secondary outcome is hip circumference before, during and after program completion

    Time frame: 12 months

  5. Change in waist circumference

    The secondary outcome is waist circumference before, during and after program completion

    Time frame: 12 months

  6. Change in blood pressure

    The secondary outcome is blood pressure before, during and after program completion

    Time frame: 12 months

  7. Change in heart rate variability

    The secondary outcome is heart rate variability before, during and after program completion

    Time frame: 12 months

  8. Change in hemoglobin A1c

    The secondary outcome is hemoglobin A1c before, during and after program completion

    Time frame: 12 months

  9. Change in perceived stress

    The secondary outcome is perceived stress before, during and after program completion as assessed by responses to the Perceived Stress Scale assessment.

    Time frame: 12 months

  10. Change in depressive symptoms

    The secondary outcome is depressive symptoms before, during and after program completion as assessed by responses to the Patient Health Questionnaire-9 (PHQ-9)

    Time frame: 12 months

  11. Change in diet

    The secondary outcome is diet before, during and after program completion as assessed by responses to the Mediterranean Eating Pattern for Americans diet adherence screener.

    Time frame: 12 months

  12. Change in activity minutes per week

    The secondary outcome is activity minutes per week before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  13. Change in daily steps total

    The secondary outcome is daily steps taken before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  14. Change in measured steps per minute

    The secondary outcome is measured steps per minute before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  15. Change in sleep quality

    The secondary outcome is sleep quality before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  16. Change in sleep duration

    The secondary outcome is sleep duration before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  17. Change in estimated energy expenditure

    The secondary outcome is estimated energy expenditure before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  18. Change in heart rate

    The secondary outcome is heart rate before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  19. Change in distance moved

    The secondary outcome is distance moved before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  20. Change in minutes of vigorous activity

    The secondary outcome is minutes of vigorous activity before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  21. Change in minutes of moderate activity

    The secondary outcome is minutes of moderate activity before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  22. Change in minutes of light activity

    The secondary outcome is minutes of light activity before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  23. Change in minutes of sedentary time

    The secondary outcome is minutes of sedentary time before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  24. Change in number of manually entered and automatically detected physical activities (walking, running, etc.)

    The secondary outcome is manually entered and automatically detected physical activities (walking, running, etc.) before, during and after program completion as assessed by smartwatch tracking.

    Time frame: 12 months

  25. Change in quality of life measures

    The secondary outcome is quality of life measures before, during and after program completion as assessed by responses to the RAND Short Form (RAND-SF 36) v1.0 survey.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Hauben J, Luthy J, Nafiu T, Brengartner A, Omar M, Nemati D, Zhao S, Brock G, Urse K, Paro J, Joseph JJ. Rationale for the Feasibility and Acceptability of Smartwatch Technology in an Exercise Regimen (FASTER) study in older individuals. Contemp Clin Trials. 2026 Jan;160:108152. doi: 10.1016/j.cct.2025.108152. Epub 2025 Nov 18. PubMed 41265833 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Apr 2026, 24 months.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 24 months is above that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion May 2026 → Apr 2026 and completion May 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Mar 1, 2024
StartActual
Mar 15, 2024
Primary completionActual
Apr 14, 2026was May 2026
CompletionActual
Apr 14, 2026was May 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 5, 2026
Primary completion
May 1, 2026→Apr 14, 2026 (actual)
Nov 5, 2026
Study completion
May 1, 2026→Apr 14, 2026 (actual)
Nov 5, 2026
Enrollment
150 (estimated)→85 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Active, not recruiting→Completed
    Primary completion May 1, 2026→Apr 14, 2026 (now actual)
    Study completion May 1, 2026→Apr 14, 2026 (now actual)
    Enrollment 150 (estimated)→85 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06287255
Responsible party
Joshua Joseph, MD (Associate Professor of Internal Medicine, Ohio State University) — Principal investigator
First posted
Mar 1, 2024
Start date
Mar 15, 2024
Primary completion
Apr 14, 2026
Completion
Apr 14, 2026
Last update
Nov 5, 2026

Study contacts

Joshua Joseph, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion